AR and prostate carcinoma: A growing body of evidence suggests that androgen receptor (AR)-targeted therapies not only fail to fully eliminate prostate cancer (PCa) cells but may also promote lineage plasticity, contributing to the development of castration-resistant prostate cancer (CRPC)—a form of the disease that continues to progress despite androgen deprivation therapy [117].